Design, synthesis, apoptotic, and antiproliferative effects of 5-chloro-3- (2-methoxyvinyl)-indole-2-carboxamides and pyrido[3,4-b]indol-1-ones as potent EGFR^WT/EGFR^T790M inhibitors

References

• You W, Henneberg M. Cancer incidence increasing globally: the role of relaxed natural selection. Evol Appl. 2018;11(2):140–152.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Al-Sanea MM, Gotina L, Mohamed MF, Grace Thomas Parambi D, Gomaa HAM, Mathew B, Youssif BGM, Alharbi KS, Elsayed ZM, Abdelgawad MA, et al. Design, synthesis and biological evaluation of new HDAC1 and HDAC2 inhibitors endowed with ligustrazine as a novel cap moiety. Drug Des Devel Ther. 2020;14:497–508.
   PubMed Web of Science ®Google Scholar
• Youssif BGM, Gouda AM, Moustafa AH, Abdelhamid AA, Gomaa HAM, Kamal I, Marzouk AA. Design and synthesis of new triaryl imidazole derivatives as dual inhibitors of BRAFV600E/p38α with potential antiproliferative activity. J. Mol. Struct. 2022;1253:132218.
   Web of Science ®Google Scholar
• Goffin JR, Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin Ther. 2013;35(9):1282–1303.
   PubMed Web of Science ®Google Scholar
• Nadeem Abbas M, Kausar S, Wang F, Zhao Y, Cui H. Advances in targeting the epidermal growth factor receptor pathway by synthetic products and its regulation by epigenetic modulators as a therapy for glioblastoma. Cells. 2019;8(4):350–361.
   PubMed Web of Science ®Google Scholar
• Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013;13(9):663–673.
   PubMed Web of Science ®Google Scholar
• Bhatia P, Sharma V, Alam O, Manaithiya A, Alam P, Alam MT, Imran M., Kahksha . Novel quinazoline-based EGFR kinase inhibitors: a review focusing on SAR and molecular docking studies (2015-2019). Eur J Med Chem. 2020;204:112640.
   PubMed Web of Science ®Google Scholar
• Wright NMA, Goss GD. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Transl Lung Cancer Res. 2019;8(Suppl 3):S247–S264.
   PubMedGoogle Scholar
• Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247.
   PubMed Web of Science ®Google Scholar
• Walter AO, Sjin RTT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013;3(12):1404–1415.
   PubMed Web of Science ®Google Scholar
• Patel H, Pawara R, Ansari A, Surana S. Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. Eur J Med Chem. 2017;142:32–47.
   PubMed Web of Science ®Google Scholar
• Shen J, Zhang T, Zhu S-J, Sun M, Tong L, Lai M, Zhang R, Xu W, Wu R, Ding J, et al. Structure-based design of 5- methylpyrimidopyridone derivatives as new wild-type sparing inhibitors of the epidermal growth factor receptor triple mutant (EGFR(L858R/T790M/C797S)). J Med Chem. 2019;62(15):7302–7308.
   PubMed Web of Science ®Google Scholar
• Mishra RDLA. Anticancer potential of plants and natural products: a review. J. Ethnopharmacol. 2013;1:622–628.
   Google Scholar
• Youssif BGM, Abdelrahman MH, Abdelazeem AH, Abdelgawad MA, Ibrahim HM, Salem OIA, Mohamed MFA, Treambleau L, Bukhari SNA. Design, synthesis, mechanistic and histopathological studies of small-molecules of novel indole-2-carboxamides and pyrazino[1,2-a]indol-1(2H)-ones as potential anticancer agents effecting the reactive oxygen species production. Eur J Med Chem. 2018;146:260–273.
   PubMed Web of Science ®Google Scholar
• Abdelrahman MH, Aboraia AS, Youssif BGM, Elsadek BEM. Design, Synthesis and Pharmacophoric Model Building of New 3-Alkoxymethyl/3-Phenyl indole-2-carboxamides with Potential Antiproliferative Activity. Chem Biol Drug Des. 2017;90(1):64–82.
   PubMed Web of Science ®Google Scholar
• Al-Wahaibi LH, Gouda AM, Abou-Ghadir OF, Salem OIA, Ali AT, Farghaly HS, Abdelrahman MH, Trembleau L, Abdu-Allah HHM, Youssif BGM, et al. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAFV600E dual inhibitors. Bioorg Chem. 2020;104:104260.
   PubMed Web of Science ®Google Scholar
• Li W, Qi Y‐Y, Wang Y‐Y, Gan Y‐Y, Shao L‐H, Zhang L‐Q, Tang Z‐H, Zhu M, Tang S‐Y, Wang Z‐C, et al. Design, synthesis, and biological evaluation of sorafenib derivatives containing indole (ketone) semicarbazide analogs as antitumor agents. J Heterocyclic Chem. 2020;57(6):2548–2560.
   Web of Science ®Google Scholar
• Singh PK, Silakari O. Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET. Bioorg Chem. 2018;79:163–170.
   PubMed Web of Science ®Google Scholar
• Song J, Yoo J, Kwon A, Kim D, Nguyen HK, Lee B-Y, Suh W, Min KH. Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases. PLoS One. 2015;10(9):e0138823.
   PubMed Web of Science ®Google Scholar
• Zhang H. Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer. Drug Des Devel Ther. 2016;10:3867–3872.
   PubMed Web of Science ®Google Scholar
• Mohamed FAM, Gomaa HAM, Hendawy OM, Ali AT, Farghaly HS, Gouda AM, Abdelazeem AH, Abdelrahman MH, Trembleau L, Youssif BGM, et al. Design, synthesis, and biological evaluation of novel EGFR inhibitors containing 5-chloro-3-hydroxymethyl-indole-2-carboxamide scaffold with apoptotic antiproliferative activity. Bioorg Chem. 2021;112:104960.
   PubMed Web of Science ®Google Scholar
• Mostafa HA, Alaa AKMH, Laurent KT. Synthesis and molecular docking of novel indole-2-carboxamide derivatives with anti-inflammatory and antinociceptive activities. J. Adv. Chem. 2014;10:3143–3159.
   Google Scholar
• Gomaa HAM, Shaker ME, Alzarea SI, Hendawy OM, Mohamed FAM, Gouda AM, Ali AT, Morcoss MM, Abdelrahman MH, Trembleau L, et al. Optimization and SAR investigation of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as EGFR and BRAFV600E dual inhibitors with potent antiproliferative and antioxidant activities. Bioorg Chem. 2022;120:105616.
   PubMed Web of Science ®Google Scholar
• Youssif BGM, Mohamed AM, Osman EEA, Abou-Ghadir OF, Elnaggar DH, Abdelrahman MH, Treamblu L, Gomaa HAM. 5-chlorobenzofuran-2-carboxamides: from allosteric CB1 modulators to potential apoptotic antitumor agents. Eur J Med Chem. 2019;177:1–11.
   PubMed Web of Science ®Google Scholar
• Mohassab AM, Hassan HA, Abdelhamid D, Gouda AM, Youssif BGM, Tateishi H, Fujita M, Otsuka M, Abdel-Aziz M. Design and Synthesis of Novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAFV600E kinases. Bioorg Chem. 2021;106:104510.
   PubMed Web of Science ®Google Scholar
• Mekheimer RA, Allam SMR, Al-Sheikh MA, Moustafa MS, Al-Mousawi SM, Mostafa YA, Youssif BGM, Gomaa HAM, Hayallah AM, Abdelaziz M, et al. Discovery of new pyrimido[5,4-c]quinolines as potential antiproliferative agents with multitarget actions: Rapid synthesis, docking, and ADME studies. Bioorg Chem. 2022;121:105693.
   PubMed Web of Science ®Google Scholar
• Ramadan M, Abd El-Aziz M, Elshaier YAMM, Youssif BGM, Brown AB, Fathy HM, Aly AA. Design and synthesis of new pyranoquinolinone heteroannulated to triazolopyrimidine of potential apoptotic antiproliferative activity. Bioorg Chem. 2020;105:104392.
   PubMed Web of Science ®Google Scholar
• El-Sherief HAM, Youssif BGM, Abdelazeem AH, Abdel-Aziz M, Abdel-Rahman HM. Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities. Anticancer Agents Med Chem. 2019;19(5):697–706.
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz SA, Taher ES, Lan P, Asaad GF, Gomaa HAM, El-Koussi NA, Youssif BGM. Design, synthesis, and biological evaluation of new pyrimidine-5-carbonitrile derivatives bearing 1,3-thiazole moiety as novel anti-inflammatory EGFR inhibitors with cardiac safety profile. Bioorg. Chem. 2021;111:104890.
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu Z, Xia S, Liu Q, Gou S. Design, synthesis, and biological evaluation of sulfamoyl phenyl quinazoline derivatives as potential EGFR/CAIX dual inhibitors. Eur J Med Chem. 2021;216:113300.
   PubMed Web of Science ®Google Scholar
• Abou-Zied HA, Youssif BGM, Mohamed MFA, Hayallah AM, Abdel-Aziz M. EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules. Bioorg Chem. 2019;89:102997.
   PubMed Web of Science ®Google Scholar
• Martin SJ. Caspases: executioners of apoptosis. Pathobiol Hum Dis. 2014;145:145–152.
   Google Scholar
• Rudel T. Caspase inhibitors in prevention of apoptosis. Herz. 1999;24(3):236–241.
   PubMed Web of Science ®Google Scholar
• Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2020.
   Google Scholar
• Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem. 2002;277(48):46265–46272.
   PubMed Web of Science ®Google Scholar
• Ibrahim TS, Bokhtia RM, Al-Mahmoudy AMM, Taher ES, AlAwadh MA, Elagawany M, Abdel-Aal EH, Panda S, Gouda AM, Asfour HZ, et al. Design, Synthesis and Biological Evaluation of Novel 5-((substituted quinolin-3-yl/1-naphthyl)methylene)-3-substituted imidazolidin-2,4-dione as HIV-1 Fusion Inhibitors. Bioorg Chem. 2020;99:103782. [InsertedFromOnlin
   PubMed Web of Science ®Google Scholar
• Shaykoon MS, Marzouk AA, Soltan OM, Wanas AS, Radwan MM, Gouda AM, Youssif BGM, Abdel-Aziz M. Design, synthesis and antitrypanosomal activity of heteroaryl-based 1,2,4-triazole and 1,3,4-oxadiazole derivatives. Bioorg Chem. 2020;100:103933.
   PubMed Web of Science ®Google Scholar
• Engel J, Becker C, Lategahn J, Keul M, Ketzer J, Mühlenberg T, Kollipara L, Schultz-Fademrecht C, Zahedi RP, Bauer S, et al. Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR. Angew Chem Int Ed. (36)2016;55:10909–10912.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.
   PubMed Web of Science ®Google Scholar